Benefits
Support for bone mineral density preservation
Long-term MK-7 supplementation has been associated with preservation of bone mineral density at the lumbar spine and femoral neck in postmenopausal women. That comes from one 3-year trial in 244 healthy postmenopausal women, and even there the decline was slowed at the spine and femoral neck but not at the total hip. The capsules tested were a fermentation-derived MK-7 from another supplier rather than K2VITAL, and the finding cannot be assumed to apply to men, to younger adults or to people with diagnosed osteoporosis. Effects support MK-7 as an adjunct to calcium and vitamin D rather than a standalone osteoporosis treatment.
Improvement in arterial stiffness markers
MK-7 supplementation has been associated with improvements in arterial stiffness measures (carotid–femoral pulse wave velocity, stiffness index) in one 3-year trial in 244 healthy postmenopausal women, consistent with the role of vitamin K2 in keeping matrix Gla protein active. Two caveats: the whole-group benefit was limited to pulse wave velocity and the stiffness index, with the other vessel measures improving only in women who started out stiffer, and no trial cited here measured arterial calcification itself. The material tested was a fermentation-derived MK-7 from another supplier, not K2VITAL.
Activation of vitamin-K-dependent proteins
MK-7 supplementation reliably reduces circulating inactive (uncarboxylated) osteocalcin and matrix Gla protein, indicating improved carboxylation status. This is where the synthetic form itself has been tested: in a study run by K2VITAL's own manufacturer, 180 mcg a day of synthetic MK-7 for 43 days raised carboxylated osteocalcin and lowered the undercarboxylated form, and a single-dose crossover found the synthetic and fermentation-derived forms bioequivalent, meaning equivalent rather than better. These are biochemical markers, not health outcomes, so they make the bone and vessel effects plausible without proving them.
Long half-life enables once-daily dosing
Compared with MK-4 (half-life ~1 hour), MK-7 has a plasma half-life of roughly 3 days. This allows once-daily dosing to maintain steady, biologically meaningful circulating levels — practical for both consumer and clinical formulations.
Soy-free, high-purity all-trans format
K2VITAL® is produced via chemical synthesis to deliver >99% all-trans MK-7 with strict control of inactive cis isomers. Because it is made by synthesis rather than by fermenting natto, it is soy free, which matters if you avoid soy. Purity and stability are manufacturing specifications, not health benefits, and the head-to-head study found the synthetic form equal to the fermentation-derived form, not better than it.
Mechanism of action
Gamma-carboxylation of Gla-domain proteins
MK-7 is an essential cofactor for the enzyme gamma-glutamyl carboxylase, which converts glutamate residues in Gla-domain proteins (osteocalcin, matrix Gla protein, GAS6, others) to gamma-carboxyglutamate, enabling these proteins to bind calcium and perform their physiological functions.
Osteocalcin activation and bone matrix formation
Carboxylated osteocalcin binds hydroxyapatite (bone mineral) and helps incorporate calcium into the bone matrix. Inadequate K2 leaves osteocalcin undercarboxylated and impairs this binding, contributing to the bone loss that comes with age.
Matrix Gla protein activation and vascular protection
Carboxylated matrix Gla protein (MGP) is the body's primary inhibitor of vascular calcification, binding calcium ions in vessel walls and limiting calcium phosphate deposition. K2 deficiency leaves MGP inactive and this pattern has been linked in observational research to more arterial calcification. No trial cited on this page measured calcification itself; the human evidence here covers arterial stiffness and MGP carboxylation only.
Long-chain menaquinone tissue distribution
Compared with shorter menaquinones, MK-7's longer isoprenoid side chain supports more efficient incorporation into circulating lipoproteins and extra-hepatic tissue delivery — explaining its disproportionate effect on extra-hepatic Gla proteins like osteocalcin and MGP relative to MK-4.
Clinical trials
Randomized, double-blind, placebo-controlled trial of MK-7 (180 mcg/day) vs placebo in 244 healthy postmenopausal women over 3 years. Outcomes: bone mineral density at lumbar spine and femoral neck, osteocalcin carboxylation status. Published in Osteoporosis International, Knapen 2013. The capsules were MenaQ7, a fermentation-derived MK-7 made by a competing supplier, not K2VITAL, and the arterial-stiffness card below reports the same 244 women rather than a second trial.
244 healthy postmenopausal women; 3-year intervention.
MK-7 supplementation significantly improved carboxylation of osteocalcin and reduced age-related decline in bone mineral content and bone mineral density at the lumbar spine and femoral neck versus placebo. Effects were modest in magnitude compared with pharmaceutical osteoporosis therapy but were statistically significant over the 3 years. At the total hip the decline was not slowed, so the result did not hold at every site measured.
Randomized, double-blind, placebo-controlled trial of MK-7 (180 µg MenaQ7/day) vs placebo in 244 healthy postmenopausal women over 3 years. Outcomes: carotid-femoral pulse wave velocity, stiffness index, circulating inactive MGP. Published in Thrombosis and Haemostasis.
244 healthy postmenopausal women; 3-year intervention.
Three-year MK-7 supplementation was associated with improvements in carotid–femoral pulse wave velocity and stiffness index versus placebo, alongside significant reductions in inactive (uncarboxylated) matrix Gla protein. Not every measure moved: distension, compliance, distensibility, Young's modulus and local carotid pulse wave velocity improved only in the women whose baseline stiffness index was above the group median, and MK-7 did not change the inflammatory markers or the markers of endothelial dysfunction. These are the vascular results of the same 244 women described in the bone card above, not a second trial.